Please login to the form below

Not currently logged in
Email:
Password:

Valeant

This page shows the latest Valeant news and features for those working in and with pharma, biotech and healthcare.

J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

Cosentyx was the first IL-17 inhibitor to reach the market and, while it has since been joined by rivals from Eli Lilly (Taltz) and Valeant (Siliq), is well ahead in

Latest news

More from news
Approximately 46 fully matching, plus 95 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    $35bn. $7.3bn. Valeant. 40. 17.5. -56%. $28bn. ($2.4bn). Perrigo. 90. 78. ... Perrigo, like Teva and Valeant, is seeking to reduce debt. Biotech companies are also selling (or licensing) assets to stay alive.

  • Deal Watch - May 2017 Deal Watch - May 2017

    is likely that in the next few months companies such as Teva and Valeant that are having a difficult time at the moment will divest parts of their business.  It is

  • Deal Watch March 2017 Deal Watch March 2017

    There are more below the radar (without accompanying numbers), for example: Valeant has granted Glycyx a sublicence to develop products containing methylnaltrexone bromide for oncology indications, and Fuji Pharma has obtained

  • Deal Watch January 2017 Deal Watch January 2017

    Bringing in an additional $819.9m in cash, Valeant also sold its equity interest in Dendreon (manufacturer of Provenge, a personalised immunotherapy) to the Sanpower Group. ... 1, 600. Valeant. L'Oreal. Divestment. CeraVe AcneFree AMBI. 1, 300. Forward

  • Deal Watch August 2016 Deal Watch August 2016

    Finally it was interesting to see that Pharming has recovered from Valeant the North American rights to its product Ruconest. ... Pharming did well to get the rights back especially as it resulted in Valeant having to make a $199m write down of its

More from intelligence
Approximately 1 fully matching, plus 31 partially matching documents found.

Latest appointments

  • ThermiGen appoints Vladimir Paul-Blanc as president ThermiGen appoints Vladimir Paul-Blanc as president

    He previously served Solta Medical - the aesthetics energy device division of Valeant Pharmaceuticals – as its general manager.

  • BMS appoints three independent directors BMS appoints three independent directors

    Robert Bertolini brings strategic and operational leadership experience from Bausch &Lomb, where he recently served as president and chief financial officer prior to the company's sale to Valeant.

  • Valeant appoints Joseph Papa to end CEO uncertainty Valeant appoints Joseph Papa to end CEO uncertainty

    Valeant's month-long search for a new chief executive has ended with its selection of Perrigo's Joseph Papa to replace current CEO Michael Pearson in early May. ... Searle &Company, Novartis and Pharmacia Corporation. He said: “I am excited to take on

  • Valeant adds member to board of directors Valeant adds member to board of directors

    President of ValueAct Capital G. Mason Morfitadded to team. Valeant Pharmaceuticals has added G. ... Morfit had originally served on Valeant's board of directors between 2007 and 2014.

  • Valeant adds Robert Hale to board of directors Valeant adds Robert Hale to board of directors

    And Jeffrey Ubben resigns from the board. Valeant has added Robert Hale, a partner at ValueAct Capital, to its board of directors. ... He said: “I have had a wonderful experience serving as director of Valeant.

More from appointments
Approximately 6 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics